Navigation Links
Epoxide hydrolase inhibition and Thiazolidinediones: A therapy for cardiometabolic syndrome
Date:4/23/2013

Scientists at the Medical College of Wisconsin and the University of California at Davis, led by Dr. John Imig and Dr. Bruce Hammock have determined the synergistic actions of inhibiting soluble epoxide hydrolase (sEH) with tAUCB (trans-4-(4-[3-adamantan-1-yl-ureid]-cyclohexyloxy)-benzoic acid) and activating peroxisome proliferator-activator receptorγ (PPARγ) with the thiazolidinedione rosiglitazone on the pathological progression of cardiometabolic syndrome. Cardiometabolic syndrome occurs with obesity and hypertension increasing the risks for cardiovascular disease and causing significant and rapidly progressive kidney disease. The findings, which appear in the December 2012 issue of Experimental Biology and Medicine, demonstrate that sEH inhibition and PPARγ activation in combination had the greatest beneficial effects on the multi-disease features and progression of kidney disease associated with cardiometabolic syndrome.

"Inhibitors of sEH have recently reached a point where their ability to combat cardiovascular and kidney diseases can be determined in humans", states Dr. Imig. "In this study we show that when used in combination with a PPARγ agonist therapy for cardiometabolic syndrome that there is a synergistic effect to decrease cardiovascular risk factors and progressive kidney disease. Another potential positive aspect of this combination therapy is that sEH inhibition has beneficial actions to counteract the edema and congestive heart failure that occurs in patients treated long-term with PPARγagonists."

Future studies would include combinational chemistry approaches to design and synthesize drugs with dual sEH inhibitory and PPARγ agonistic activities. Dr. Hammock states, "these approaches are currently being done by his laboratory and others". He also says "that combining sEH inhibition not just with PPARγ but also with other therapies for cardiovascular, inflammatory, and renal diseases are on the horizon and have therapeutic potential as both drug combinations and dual sEH inhibitors with PPARγ activity for treating cardiometabolic syndrome."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said, " This study by John Imig and Bruce Hammack, performed on spontaneous hypertensive and spontaneous hypertensive obese rat models, suggests that a combined therapy with epoxide hydrolase inhibitors and thiazolidinediones may prove to be efficacious in treatment of the multi-disease characteristics of cardiometabolic syndrome. "


'/>"/>

Contact: John Imig
jdimig@mcw.edu
Society for Experimental Biology and Medicine
Source:Eurekalert

Related medicine news :

1. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
2. Novel test identifies patients most likely to benefit from ALK inhibition therapy
3. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
4. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
5. Palliative radiotherapy for bone metastases in elderly patients improves quality of life
6. Physical Therapy Exercises
7. How “Post Rehab Essentials” Helps People Learn About Post Rehab – V kool
8. Intensity modulated radiotherapy reduces side effects in patients with early breast cancer
9. New radiotherapy approach reduces symptoms of dry mouth in patients with head and neck cancers
10. 2 landmark studies report on success of using image-guided brachytherapy to treat cervical cancer
11. Early cognitive behavioural therapy reduces risk of psychosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... Roxanna Cross ... p.m. at the 11th Annual RISE Nashville Summit. RISE Nashville is the healthcare ... and engagement strategies. , The discussion will include best practices for accurate identification ...
(Date:2/27/2017)... ... February 27, 2017 , ... Robert E. Burke, MD, PhD, ... But his impoverished upbringing and life experiences could have led him down a much ... and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal account ...
(Date:2/27/2017)... ... ... Carothers is not your typical author. She went from working as a movie extra on ... God, when she isn’t swimming as a performing mermaid. , Her book isn’t typical either. ... offers a comedic look at the dysfunctions of God’s family, before Lucifer was sent to ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... an upgrade to the company's Yelp listing. Bay Area residents struggling from thinning ... as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... marks the passing of one if its founding fathers, Dr. Eugene ... the service of scientific and scholarly research. A pioneer in the practice ... the way researchers work with the literature, Garfield passed away suddenly on ... ... Dr. Eugene Garfield, founding father ...
(Date:2/28/2017)... This report provides all the information you ... and activities since 2010. Download the full ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:2/28/2017)...   Fourth-quarter 2016 revenues ... million to top end of guidance ... charges in fourth-quarter 2016 associated with the write-down of ... Generics reporting unit Fourth-quarter ... operations; Full-year 2016 reported $14.48 diluted (GAAP) loss per ...
Breaking Medicine Technology: